Ketamine-induced brain activation in awake female nonhuman primates: a translational functional imaging model
- 10 December 2015
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 233 (6) , 961-972
Abstract
Rationale There is significant interest in the NMDA receptor antagonist ketamine due to its efficacy in treating depressive disorders and its induction of psychotic-like symptoms that make it a useful tool for modeling psychosis. Objective The present study extends the successful development of an apparatus and methodology to conduct pharmacological MRI studies in awake rhesus monkeys in order to evaluate the CNS effects of ketamine. Methods Functional MRI scans were conducted in four awake adult female rhesus monkeys during sub-anesthetic intravenous (i.v.) infusions of ketamine (0.345 mg/kg bolus followed by 0.256 mg/kg/h constant infusion) with and without risperidone pretreatment (0.06 mg/kg). Statistical parametric maps of ketamine-induced blood oxygenation level–dependent (BOLD) activation were obtained with appropriate general linear regression models (GLMs) incorporating motion and hemodynamics of ketamine infusion. Results Ketamine infusion induced and sustained robust BOLD activation in a number of cortical and subcortical regions, including the thalamus, cingulate gyrus, and supplementary motor area. Pretreatment with the antipsychotic drug risperidone markedly blunted ketamine-induced activation in many brain areas. Conclusions The results are remarkably similar to human imaging studies showing ketamine-induced BOLD activation in many of the same brain areas, and pretreatment with risperidone or another antipsychotic blunting the ketamine response to a similar extent. The strong concordance of the functional imaging data in humans with these results from nonhuman primates highlights the translational value of the model and provides an excellent avenue for future research examining the CNS effects of ketamine. This model may also be a useful tool for evaluating the efficacy of novel antipsychotic drugs.Keywords
Funding Information
- Sunovion Pharmaceutical, Ltd
- Yerkes National Primate Research Center (P51OD11132)
- National Institute on Drug Abuse (DA031246)
This publication has 49 references indexed in Scilit:
- Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and BeyondBiological Psychiatry, 2013
- Quantifying the Attenuation of the Ketamine Pharmacological Magnetic Resonance Imaging Response in Humans: A Validation Using Antipsychotic and Glutamatergic AgentsThe Journal of Pharmacology and Experimental Therapeutics, 2013
- NMDA receptor blockade at rest triggers rapid behavioural antidepressant responsesNature, 2011
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA AntagonistsScience, 2010
- Development of an apparatus and methodology for conducting functional magnetic resonance imaging (fMRI) with pharmacological stimuli in conscious rhesus monkeysJournal of Neuroscience Methods, 2010
- Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled studyPain, 2009
- Antipsychotic drug-induced weight gain mediated by histamine H1receptor-linked activation of hypothalamic AMP-kinaseProceedings of the National Academy of Sciences, 2007
- Processing Words with Emotional Connotation: An fMRI Study of Time Course and Laterality in Rostral Frontal and Retrosplenial CorticesJournal of Cognitive Neuroscience, 2004
- AFNI: Software for Analysis and Visualization of Functional Magnetic Resonance NeuroimagesComputers and Biomedical Research, 1996
- Improved Assessment of Significant Activation in Functional Magnetic Resonance Imaging (fMRI): Use of a Cluster‐Size ThresholdMagnetic Resonance in Medicine, 1995